Align Technology (NASDAQ:ALGN – Get Free Report) and Nexalin Technology (NASDAQ:NXL – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.
Risk & Volatility
Align Technology has a beta of 1.74, suggesting that its share price is 74% more volatile than the S&P 500. Comparatively, Nexalin Technology has a beta of 4.31, suggesting that its share price is 331% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations for Align Technology and Nexalin Technology, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Align Technology | 1 | 7 | 8 | 1 | 2.53 |
| Nexalin Technology | 1 | 1 | 0 | 0 | 1.50 |
Align Technology currently has a consensus price target of $193.08, suggesting a potential upside of 14.71%. Given Align Technology’s stronger consensus rating and higher probable upside, research analysts plainly believe Align Technology is more favorable than Nexalin Technology.
Valuation & Earnings
This table compares Align Technology and Nexalin Technology”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Align Technology | $4.03 billion | 2.94 | $410.35 million | $6.87 | 24.50 |
| Nexalin Technology | $300,000.00 | 3.60 | -$8.22 million | ($14.41) | -0.10 |
Align Technology has higher revenue and earnings than Nexalin Technology. Nexalin Technology is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Align Technology and Nexalin Technology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Align Technology | 11.83% | 15.96% | 10.48% |
| Nexalin Technology | -3,384.12% | -344.93% | -248.12% |
Insider and Institutional Ownership
88.4% of Align Technology shares are owned by institutional investors. Comparatively, 0.7% of Nexalin Technology shares are owned by institutional investors. 0.7% of Align Technology shares are owned by insiders. Comparatively, 16.9% of Nexalin Technology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Align Technology beats Nexalin Technology on 12 of the 15 factors compared between the two stocks.
About Align Technology
Align Technology, Inc. develops, manufactures and markets digital orthodontic and restorative dentistry products. Its best-known offering is the Invisalign system, which uses a series of custom-made clear aligners to straighten teeth. The company also sells Vivera retainers and iTero intraoral scanners, which support digital dental imaging and treatment planning. Founded in 1997, Align helped popularize clear-aligner orthodontic treatment as an alternative to traditional braces. Its digital dentistry portfolio also includes exocad software, used by dental professionals and laboratories to design dental restorations.
About Nexalin Technology
Nexalin Technology, Inc. (NASDAQ:NXL) is a medical technology company focused on developing and commercializing noninvasive neurostimulation devices for mental health and neurological applications. Its technology is designed to deliver low-intensity electrical stimulation to the brain with the goal of influencing neural activity associated with conditions such as depression, anxiety, insomnia, post-traumatic stress disorder and substance-use disorders. The company’s product portfolio includes the Gen-2 and Gen-3 neurostimulation systems.
Receive News & Ratings for Align Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology and related companies with MarketBeat.com's FREE daily email newsletter.
